FDA warns US firms over inadequate testing, lax process controls
Regulatory NewsJoanne S. Eglovitch
Audit/inspectionCDERComplianceGMPOTCPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)Warning letters